醋酸乌利司他改善子宫腺肌病合并子宫肌瘤女性的临床症状
回顾性单中心观察研究纳入163例绝经前女性,比较子宫腺肌病合并症状性子宫肌瘤41例与仅肌瘤122例接受首疗程醋酸乌利司他5 mg/d共12周的效果。腺肌病组合并肌瘤组闭经率90.4%高于仅肌瘤组77.6%(p=.0017),最佳出血控制率亦更高(90.2% vs 73.8%,p=.028)。作者认为醋酸乌利司他可能是子宫腺肌病的一种良好替代治疗。
要点
- 腺肌病合并肌瘤组首疗程醋酸乌利司他后闭经率90.4%,仅肌瘤组77.6%,差异有统计学意义(p=.0017)。
- 最佳出血控制(PBAC<75)腺肌病合并肌瘤组90.2%,高于仅肌瘤组73.8%(p=.028)。
- 两研究组生活质量均改善,自评整体健康状况变好比例腺肌病合并肌瘤组67.00%、仅肌瘤组80.50%(p=.223)。
核心结论
- 醋酸乌利司他治疗使合并子宫肌瘤的子宫腺肌病女性出血和疼痛等临床症状显著减轻,并获得高闭经率。
- 尽管研究存在局限,作者认为醋酸乌利司他可能是子宫腺肌病的一种良好替代治疗。
研究设计与样本
- 回顾性单中心观察性研究(加拿大特别工作组分类II-2)。
- 在大学三级转诊中心开展。
- 纳入163例绝经前女性,其中子宫腺肌病合并症状性子宫肌瘤41例(A+F组),仅子宫肌瘤122例(F组)。
- 干预为首疗程醋酸乌利司他5 mg/d,共12周。
主要发现
- 闭经率A+F组90.4% vs F组77.6%(p=.0017)。
- 最佳出血控制率(PBAC<75)A+F组90.2% vs F组73.8%(p=.028)。
- 首疗程结束时自报视觉模拟量表评分A+F组显著高于F组(p=.017),反映腺肌病女性疼痛改善更大。
- 两研究组生活质量均改善。
- 自评整体健康状况较治疗前变好者A+F组67.00% vs F组80.50%(p=.223)。
临床怎么用
- 作者认为醋酸乌利司他可能是子宫腺肌病的一种良好替代治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY OBJECTIVE: To study the effects of ulipristal acetate (UPA) on adenomyosis-associated clinical symptoms. DESIGN: A retrospective, single-center observational study (Canadian Task Force classification II-2). SETTING: A university tertiary referral center. PATIENTS: Premenopausal women (163) with adenomyosis and symptomatic uterine myomas (41 patients, A + F group) versus a control group with only myomas (122 patients, F group) treated with the first course of UPA. INTERVENTIONS: This was a retrospective study to assess the effects of a 12-week course of UPA (5 mg/d). MEASUREMENTS AND MAIN RESULTS: Clinical symptoms including bleeding control, amenorrhea, pain outcomes, and self-perceived severity of the disease and quality of life. Amenorrhea was present in 90.4% of the A + F group compared with 77.6% in the F group (p = .0017). Optimal bleeding control was significantly higher in the adenomyosis group (pictorial blood loss assessment chart < 75) than in the F group (90.2% vs 73.8%, p = .028). At the end of the first UPA course, the self-reported visual analog scale scores in the A + F group were significantly higher than in the F group (p = .017), reflecting greater improvement in pain outcomes for women with adenomyosis. UPA treatment improved the quality of life in both study groups. Most of the women rated their global health status as "better" after the first UPA course than before the treatment (A + F group: 67.00% and F group: 80.50%, p = .223). CONCLUSION: Treatment with UPA led to a significant reduction in the clinical symptoms of adenomyosis (bleeding and pain) and achieved a high rate of amenorrhea in a cohort of women with concomitant uterine myomas. Despite the limitations of the study, our results showed that UPA might be a good alternative treatment for adenomyosis.
引用
- Gracia M, Alcalà M, Ferreri J, et al. Ulipristal Acetate Improves Clinical Symptoms in Women with Adenomyosis and Uterine Myomas. J Minim Invasive Gynecol. 2018. PMID: 29626678. doi:10.1016/j.jmig.2018.04.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。